Edition:
United Kingdom

Miragen Therapeutics Inc (MGEN.OQ)

MGEN.OQ on NASDAQ Stock Exchange Capital Market

8.04USD
22 Nov 2017
Change (% chg)

-- (--)
Prev Close
$8.04
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
22,776
52-wk High
$17.83
52-wk Low
$4.65

Latest Key Developments (Source: Significant Developments)

Miragen Therapeutics reports third quarter financial results
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Miragen Therapeutics Inc :Miragen Therapeutics reports third quarter 2017 financial results and provides corporate update.Q3 revenue $1.6 million versus $900,000.Q3 revenue view $306,000 -- Thomson Reuters I/B/E/S.Miragen Therapeutics Inc - ‍cash and cash equivalents at september 30, 2017 were $42.8 million, compared to $22.1 million at December 31, 2016​.Miragen Therapeutics Inc - qtrly ‍net loss per share, basic and diluted $0.27​.  Full Article

Signal Genetics receives extension to comply with Nasdaq continued listing requirement
Thursday, 26 May 2016 

Signal Genetics Inc : Signal Genetics receives extension to comply with Nasdaq continued listing requirement .Received notification from Nasdaq that it has an additional 180-day period, or until November 21, 2016, to regain compliance.  Full Article

Signal Genetics Q1 loss per share $0.26
Monday, 16 May 2016 

Signal Genetics Inc : Qtrly loss per share $0.26 . Q1 earnings per share view $-0.28, revenue view $750,000.00 -- Thomson Reuters I/B/E/S . Signal genetics highlights recent achievements and reports first quarter 2016 financial results .Q1 revenue $818,000 versus $645,000.  Full Article

BRIEF-Miragen Therapeutics says entered into amended and restated loan and security agreement with Silicon Valley Bank ​

* Miragen Therapeutics says ‍on Nov 14, entered into amended and restated loan and security agreement with Silicon Valley Bank - SEC Filing ​